Unclassifiable Invasive Pulmonary Aspergillosis in the ICU: insights from a multicenter, retrospective cohort study in France (2022-2024)

Clicks: 2
ID: 325604
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #112 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Suspected invasive pulmonary aspergillosis (IPA) is increasingly treated in intensive care, including in patients without classical immunosuppression. Whether current research definitions (EORTC/MSGERC, FUNDICU) classify treated cases and predict mortality is unclear. Methods We retrospectively included adults in 48 French intensive care units who received systemic antifungal therapy for suspected IPA (January 2022-July 2024). Patients were categorized as having modified EORTC/MSGERC probable IPA, FUNDICU probable IPA, or unclassified. Ninety-day mortality was analyzed using multivariable Cox regression; heterogeneity was explored with unsupervised clustering. Results Among 371 treated patients, 217 (58%) met modified EORTC, 83 (22%) met FUNDICU, and 71 (19%) were unclassified. Overall, 90-day mortality was 62% and survival did not differ by category (63%, 63%, 58%; log-rank p=0.24). In adjusted analyses, IPA categorization was not associated with mortality (FUNDICU vs EORTC: adjusted hazard ratio (aHR)=0.86, 95% CI 0.62-1.20; unclassified vs EORTC: aHR=0.89, 0.62-1.30). Age (aHR 1.03/year, 1.02-1.05), SOFA (1.06/point, 1.03-1.10), and frailty (1.17/point, 1.07-1.30) independently predicted 90-day mortality. Exploratory clustering identified six phenotypes with 90-day mortality ranging from 40% to 80%. Conclusions Nearly one in five intensive care patients treated for suspected IPA were not classifiable by EORTC/MSGERC or FUNDICU definitions. Mortality was more strongly associated with age, frailty and acute severity than with classification category, supporting ICU-focused diagnostic frameworks and risk stratification; these associations should be read in light of the treatment-based design and do not establish that the definitions lack diagnostic value.
Reference Key
openalex_W7203769604 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Antoine Villa, Benoît Painvin, Antoine Hérault, Pierre-Marie Bourgeois, Bastien Peiffer, Sibylle Cunat, Fanny Vincent, Luc Juban, Luc Desmedt, Marine De Bony, Marin Caumartin, Rania Bounab, Loïc Prez, Julien Dessajan, François Dhelft, Jérémie Mallet, Marc Pineton de Chambrun, Grégoire Fourcade, Cédric Darreau, Donatien de Marignan, Guillaume Louis, Florent Wallet, Maxime Desgrouas, Kévin Vanneck Kamdem, Hamza Chraïbi, Florian Reizine, Tomas Urbina, Françoise Botterel, Fanny Lanternier, Laurence Millon, Saad Nseir, Nicolas de Prost, the ASPIRE Study Group Collaborators, Jonathan Chelly, Marc Gainnier, Octave Cannac, Martin Cour, Emmanuelle Guérin, Sébastien Jochmans, Loïc Le Guennec, Damien Contou, Adrien Pons, Jean‐Pierre Quenot, Fabrice Uhel, Asaël Berger, Maxens Decavèle, Antoine Guillon, Pascal Beuret, Cindy Lage, Djamel Mokart, Octave Cannac, Victor Penaud, Antoine Lafarge, Julien Maizel, Rémy Nyga, Jean-Philippe Rigaud, Matthieu Turpin, Sophie Nagle, Pierre Bay, Keyvan Razazi
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag519
URL
https://doi.org/10.1093/ofid/ofag519
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.